Source: Kingfisher Biotech, Inc. submitted to NRP
DEVELOPMENT OF ATLANTIC BOTTLENOSE DOLPHIN CYTOKINE ASSAYS AS DIAGNOSTIC MARKERS OF INFECTION, TO MONITOR IMMUNE FUNCTION TO VACCINATION
Sponsoring Institution
Agricultural Research Service/USDA
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
0425081
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Jun 26, 2013
Project End Date
Dec 31, 2014
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
Kingfisher Biotech, Inc.
1000 Westgate Drive
St. Paul,MN 55114
Performing Department
(N/A)
Non Technical Summary
(N/A)
Animal Health Component
40%
Research Effort Categories
Basic
50%
Applied
40%
Developmental
10%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3113310103050%
3113410104050%
Goals / Objectives
The objective of this cooperative research project is to develop cytokine assays for Atlantic bottlenose dolphins.
Project Methods
To begin with, proinflammatory molecules (IL-1beta, IL-8, TNF-alpha, IL-12), and type I (IFN-gamma), as well as type II (e.g., IL-10, IL-13) cytokine reagents will be proposed for development. The reasons for this selected set is as follows. As the name implies, pro-inflammatory cytokines play a critical role in mediating inflammatory processes. Type I cytokines are critical for cell-mediated immune responses to intracellular pathogens. Type II responses facilitate the production of specific classes of antibody. These cytokines would be expressed as recombinant proteins as follows: Mature proteins would be expressed using an expression vector with its own signal sequence and transfected into yeast (Pichia pastoris). Expressed proteins will be purified by high performance liquid chromatography (HPLC). A collaborator has expertise with this system. Bioassays will be used for testing the bioactivity of recombinant cytokines. Several of these assays have been successfully used for measuring bioactivity of cytokines from a wide variety of species (e.g., cattle, swine, poultry, and fish). Once bioactivity of each cytokine has been confirmed, polyclonal antibodies (pAb) to select recombinant cytokines will be produced in rabbits. Monoclonal antibodies (mAb) to specific cytokines (e.g., IFN-gamma and IL-13) would be produced in mice. Development of ELISA assays. ELISAs will be developed using two pAb, two mAb, or a mAb and a pAb along with the appropriate recombinant cytokine. Standard curves will be used to quantify the levels of cytokines in blood or in cultures of cetacean leukocytes. Development of ELISAs will allow for the evaluation of functional changes in the T. truncatus immune system in response to environmental insults, infectious diseases, and/or vaccination. This will be of substantial benefit to monitoring bottlenose dolphin health.